Can artificial intelligence identify effective COVID-19 therapies?
Michael B SchultzDaniel VeraDavid A SinclairPublished in: EMBO molecular medicine (2020)
In this issue of EMBO Molecular Medicine, Stebbing et al (2020b) validate an artificial intelligence-assisted prediction that a drug used to treat rheumatoid arthritis could be a potent weapon against COVID-19. Using liver organoids infected with SARS-CoV-2, they confirm dual antiviral and anti-inflammatory activities and show that its administration in four COVID-19 patients is correlated with disease improvement, paving the way for more rigorous placebo-controlled trials.
Keyphrases
- artificial intelligence
- sars cov
- anti inflammatory
- machine learning
- rheumatoid arthritis
- big data
- deep learning
- respiratory syndrome coronavirus
- placebo controlled
- coronavirus disease
- double blind
- disease activity
- study protocol
- randomized controlled trial
- clinical trial
- squamous cell carcinoma
- emergency department
- ankylosing spondylitis
- radiation therapy
- phase iii
- idiopathic pulmonary fibrosis
- phase ii
- electronic health record